BLOO7 schreef op 8 augustus 2018 10:14:
[...]
clinicaltrials.gov/ct2/show/NCT028739...Dit tipje van de sluier werd op 3 augustus opgelicht:
Over Fase 3 resultaten finch 2 RA met filgotinib.
Walid Abi-Saab Well Look, I think, we will have to wait until we have the totality of the data for Phase III program to be able to make that statement with more confidence. But so far based on data that we have seen today and based on what we know about the drug and its selectivity, and it's emerging safety profile, we expected
to be best-in- class. And we show best-in-class you will be used much more commonly than otherwise. It's very difficult to make predictions without the data.
But so far what we know of promises to be a very good profile at the completion of Phase III